Comparative Pharmacology
Head-to-head clinical analysis: CAPEX versus CORMAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPEX versus CORMAX.
CAPEX vs CORMAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties.
Corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive effects. Binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine release.
Topical application of a thin film twice daily to affected areas. Not for ophthalmic, oral, or intravaginal use.
2.5 mg orally twice daily; maximum 10 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5–2 hours. This short half-life supports twice-daily dosing for maintenance of therapeutic levels.
Terminal elimination half-life: 3.5 hours (range 2.5-4.5 h); clinical context: dosing every 4-6 hours to maintain therapeutic levels
Primarily renal (hepatic metabolism to inactive metabolites; <1% excreted unchanged in urine). Fecal elimination accounts for <5%.
Renal: 90% unchanged; minor biliary/fecal: <5%
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid